Overview

Preclinical Imaging (In-VIVO) Market Overview:

FutureWise Market Research has instantiated a report that provides an intricate analysis of Preclinical Imaging (In-VIVO) Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Preclinical Imaging (In-VIVO) Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Preclinical Imaging (In-VIVO) Market:
• PerkinElmer, Inc. (U.S.)
• Bruker Corporation (U.S.)
• Fujifilm Holdings Corporation (Japan)
• Mediso Ltd. (Hungary)
• MILabs B.V. (Netherlands)
• MR Solutions (U.K.)
• LI-COR Biosciences (U.S.)
• Aspect Imaging (Israel)
• TriFoil Imaging (U.S.)
• Miltenyi Biotech GmbH (Germany)
• Takara Bio
• Carestream Health
• Evrogen
• Agilent Technologies
• BD Biosciences
(Note: The list of the major players will be updated with the latest market scenario and trends)

Preclinical Imaging (In-VIVO) Market Segmentation:
By Modality
• Optical Imaging Systems
 o Bioluminescence/Fluorescence Imaging Systems
 o Standalone Fluorescence Imaging Systems
 o Optical + X-Ray/Optical + CT
• Nuclear Imaging Systems
 o Micro-PET Systems
   o Standalone PET Systems
   o PET/CT Systems
   o PET/MRI Systems
 o Micro-SPECT Systems
   o Standalone Spect Systems
   o Spect/CT Systems
   o Spect/MRI Systems
 o Trimodality (SPECT/PET/CT) Systems
• Micro-MRI
• Micro-Ultrasound
• Micro-CT
• Photoacoustic Imaging Systems
• Magnetic Particle Imaging (MPI) Systems
By Reagent
• Preclinical Optical Imaging Reagents
 o Bioluminescent Imaging Reagents
   o Luciferins
   o Proluciferins
   o Coelenterazine
   o Other Bioluminescent Imaging Reagents
 o Fluorescent Imaging Reagents
   o Green Fluorescent Proteins
   o Red Fluorescent Proteins
   o Infrared Dyes
   o Other Fluorescent Imaging Reagents
• Preclinical Nuclear Imaging Reagents
 o Preclinical PET Tracers
   o Fluorine-18-Based Preclinical PET Tracers
   o Carbon-11-Based Preclinical PET Tracers
   o Copper-64-Based Preclinical PET Tracers
   o Other PET Tracers
 o Preclinical SPECT Probes
   o Technetium-99m-Based Preclinical Spect Probes
   o Iodine-131-Based Preclinical Spect Probes
   o Gallium-67-Based Preclinical Spect Probes
   o Thallium-201-Based Preclinical Spect Probes
   o Other Spect Probes
• Preclinical MRI Contrast Agents
 o Gadolinium-based Preclinical MRI Contrast Agents
 o Iron-based Preclinical MRI Contrast Agents
 o Manganese-based Preclinical MRI Contrast Agents
• Preclinical Ultrasound Contrast Agents
• Preclinical CT Contrast Agents
 o Iodine-based Preclinical CT Contrast Agents
 o Barium-based Preclinical CT Contrast Agents
 o Gold Nanoparticles
 o Gastrografin-based Preclinical CT Contrast Agents
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Preclinical Imaging (In-VIVO) Market By Modality,By Reagent and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Preclinical Imaging (In-VIVO) Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Preclinical Imaging (In-VIVO) Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Preclinical Imaging (In-VIVO) Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Preclinical Imaging (In-VIVO) Market,By Modality Historical Analysis and Forecast 2022-2028 (USD Million)
  7.1. Optical Imaging Systems
       7.1.1. Bioluminescence/Fluorescence Imaging Systems
       7.1.2. Standalone Fluorescence Imaging Systems
       7.1.3. Optical + X-Ray/Optical + CT
  7.2. Nuclear Imaging Systems
       7.2.1. Micro-PET Systems
              7.2.1.1. Standalone PET Systems
              7.2.1.2. PET/CT Systems
              7.2.1.3. PET/MRI Systems
       7.2.2. Micro-SPECT Systems
              7.2.2.1. Standalone Spect Systems
              7.2.2.2. Spect/CT Systems
              7.2.2.3. Spect/MRI Systems
       7.2.3. Trimodality (SPECT/PET/CT) Systems
  7.3. Micro-MRI
  7.4. Micro-Ultrasound
  7.5. Micro-CT
  7.6. Photoacoustic Imaging Systems
  7.7. Magnetic Particle Imaging (MPI) Systems

8. Preclinical Imaging (In-VIVO) Market,By Reagent Historical Analysis and Forecast 2022-2028 (USD Million)  
  8.1. Preclinical Optical Imaging Reagents
       8.1.1. Bioluminescent Imaging Reagents
              8.1.1.1. Luciferins
              8.1.1.2. Proluciferins
              8.1.1.3. Coelenterazine
              8.1.1.4. Other Bioluminescent Imaging Reagents
       8.1.2. Fluorescent Imaging Reagents
              8.1.2.1. Green Fluorescent Proteins
              8.1.2.2. Red Fluorescent Proteins
              8.1.2.3. Infrared Dyes
              8.1.2.4. Other Fluorescent Imaging Reagents
  8.2. Preclinical Nuclear Imaging Reagents
       8.2.1. Preclinical PET Tracers
              8.2.1.1. Fluorine-18-Based Preclinical PET Tracers
              8.2.1.2. Carbon-11-Based Preclinical PET Tracers
              8.2.1.3. Copper-64-Based Preclinical PET Tracers
              8.2.1.4. Other PET Tracers
       8.2.2. Preclinical SPECT Probes
              8.2.2.1 Technetium-99m-Based Preclinical Spect Probes
              8.2.2.2 Iodine-131-Based Preclinical Spect Probes
              8.2.2.3 Gallium-67-Based Preclinical Spect Probes
              8.2.2.4 Thallium-201-Based Preclinical Spect Probes
              8.2.2.5 Other Spect Probes
  8.3. Preclinical MRI Contrast Agents
       8.3.1. Gadolinium-based Preclinical MRI Contrast Agents
       8.3.2. Iron-based Preclinical MRI Contrast Agents
       8.3.3. Manganese-based Preclinical MRI Contrast Agents
  8.4. Preclinical Ultrasound Contrast Agents
  8.5. Preclinical CT Contrast Agents
       8.5.1. Iodine-based Preclinical CT Contrast Agents
       8.5.2. Barium-based Preclinical CT Contrast Agents
       8.5.3. Gold Nanoparticles
       8.5.4. Gastrografin-based Preclinical CT Contrast Agents

9. North America Preclinical Imaging (In-VIVO) Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
  9.1. Introduction
  9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
       9.2.1. U.S.A
       9.2.2. Canada
       9.2.3. Mexico
  9.3. Market Size (USD Million) Forecast for North America 2022-2028

10. Latin America Preclinical Imaging (In-VIVO) Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   10.1. Introduction
   10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         10.2.1. Brazil
         10.2.2. Venezuela
         10.2.3. Argentina
         10.2.4. Rest of Latin America
   10.3. Market Size (USD Million) Forecast for Latin America 2022-2028

11. Europe Preclinical Imaging (In-VIVO) Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         11.2.1. Germany
         11.2.2. U.K        
         11.2.3. France
         11.2.4. Italy
         11.2.5. Spain
         11.2.6. Russia
         11.2.7. Poland
         11.2.8. Rest of Europe
   11.3. Market Size (USD Million) Forecast for Europe 2022-2028

12. Asia Pacific Preclinical Imaging (In-VIVO) Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         12.2.1. Japan
         12.2.2. China
         12.2.3. India
         12.2.4. Australia and New Zealand
         12.2.5. ASEAN
         12.2.6. Rest of Asia Pacific
   12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

13. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         13.2.1. GCC
         13.2.2. Israel
         13.2.3. South Africa
         13.2.4. Rest of MEA
   13.3. Market Size (USD Million) Forecast for MEA 2022-2028

14. Market Share Analysis and Competitive Landscape  
   14.1. Global Landscape - Key Players, Revenue and Presence
   14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   14.3. Global Emerging Companies
   14.4.  North America - Market Share Analysis and Key Regional Players
   14.5.  Europe - Market Share Analysis and Key Regional Players
   14.6.  Asia Pacific - Market Share Analysis and Key Regional Players
   14.7.  Global Key Player - Growth Matrix

15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   15.1. PerkinElmer, Inc. (U.S.)
         15.1.1. Company Overview
         15.1.2. Product Portfolio
         15.1.3. SWOT Analysis
         15.1.4. Financial Overview
         15.1.5. Strategic Overview
   15.2. Bruker Corporation (U.S.)
         15.2.1. Company Overview
         15.2.2. Product Portfolio
         15.2.3. SWOT Analysis
         15.2.4. Financial Overview
         15.2.5. Strategic Overview                        
   15.3. Fujifilm Holdings Corporation (Japan)
         15.3.1. Company Overview
         15.3.2. Product Portfolio
         15.3.3. SWOT Analysis
         15.3.4. Financial Overview
         15.3.5. Strategic Overview
   15.4. Mediso Ltd. (Hungary)
         15.4.1. Company Overview
         15.4.2. Product Portfolio
         15.4.3. SWOT Analysis
         15.4.4. Financial Overview
         15.4.5. Strategic Overview
   15.5. MILabs B.V. (Netherlands)
         15.5.1. Company Overview
         15.5.2. Product Portfolio
         15.5.3. SWOT Analysis
         15.5.4. Financial Overview
         15.5.5. Strategic Overview          
   15.6. MR Solutions (U.K.)
         15.6.1. Company Overview
         15.6.2. Product Portfolio
         15.6.3. SWOT Analysis
         15.6.4. Financial Overview
         15.6.5. Strategic Overview      
   15.7. LI-COR Biosciences (U.S.)
         15.7.1. Company Overview
         15.7.2. Product Portfolio
         15.7.3. SWOT Analysis
         15.7.4. Financial Overview
         15.7.5. Strategic Overview
   15.8. Aspect Imaging (Israel)
         15.8.1. Company Overview
         15.8.2. Product Portfolio
         15.8.3. SWOT Analysis
         15.8.4. Financial Overview
         15.8.5. Strategic Overview
   15.9. TriFoil Imaging (U.S.)
         15.9.1. Company Overview
         15.9.2. Product Portfolio
         15.9.3. SWOT Analysis
         15.9.4. Financial Overview
         15.9.5. Strategic Overview
   15.10.Miltenyi Biotech GmbH (Germany)        
         15.10.1. Company Overview
         15.10.2. Product Portfolio
         15.10.3. SWOT Analysis
         15.10.4. Financial Overview
         15.10.5. Strategic Overview
   15.11.Takara Bio
         15.11.1. Company Overview
         15.11.2. Targeted Antigen Portfolio
         15.11.3. SWOT Analysis
         15.11.4. Financial Overview
         15.11.5. Strategic Overview
   15.12.Carestream Health
         15.12.1. Company Overview
         15.12.2. Targeted Antigen Portfolio
         15.12.3. SWOT Analysis
         15.12.4. Financial Overview
         15.12.5. Strategic Overview
   15.13.Evrogen
         15.13.1. Company Overview
         15.13.2. Targeted Antigen Portfolio
         15.13.3. SWOT Analysis
         15.13.4. Financial Overview
         15.13.5. Strategic Overview
   15.14.Agilent Technologies
         15.14.1. Company Overview
         15.14.2. Targeted Antigen Portfolio
         15.14.3. SWOT Analysis
         15.14.4. Financial Overview
         15.14.5. Strategic Overview
   15.15.BD Biosciences
         15.15.1. Company Overview
         15.15.2. Targeted Antigen Portfolio
         15.15.3. SWOT Analysis
         15.15.4. Financial Overview
         15.15.5. Strategic Overview
 
16. Pre and Post COVID-19 Impact
   16.1. Positive influence on the healthcare industry
   16.2. The financial disruption of the manufacturing sector
   16.3. Impact of COVID-19 on emerging companies
   16.4. Significant mandates in the healthcare regulations initiated by administrations
   16.5. The overall economic slowdown of the developing and developed nations

17. FutureWise SME Key Takeaway Points for Client

Tables

Figures